Evotec on the brink of acquisition: What does it mean for the biotech industry?
This issue of our newsletter is supported by Thermo Fisher Scientific.
Evotec has been part of the European biotech landscape since 1993 and stands out as a rare breed: part service provider, part innovator. This dual model gives Evotec both the stability of service revenues and the high-risk, high-reward potential of developing its own medicines. But things are not going to plan of late.
2024 has brought major financial struggles for the company, leading to layoffs and the closure of its gene therapy operations. And now, industry players seem poised to capitalize on this rough patch; Triton Partners recently acquired nearly 10% of Evotec, and Halozyme Therapeutics has made an unsolicited $2.1 billion acquisition offer.
But what exactly does this mean for the European biotech industry, and what might the future hold for one of its most versatile players?
To find out more, read the full article: “Evotec on the brink of acquisition: At what cost for the biotech industry?”
A MESSAGE FROM OUR SPONSOR THERMO FISHER SCIENTIFIC
Driven by performance
From innovative monoclonal antibodies to life-changing cell therapies, biotech pioneers are relentlessly pursuing performance. Unlock your edge and carve a path to success with the comprehensive range of Gibco? solutions and services, designed to help you streamline your workflow and fast-track your therapy.
Want to advertise with us? Become our next sponsor.
?? More noteworthy articles from this week:
A rare condition in which the body produces abnormally low levels of a hormone called the parathyroid hormone (PTH), which is key to regulating and maintaining a balance of calcium and phosphorus in the body, hypoparathyroidism can potentially lead to chronic kidney disease. While hypoparathyroidism may not be known to many, the treatment landscape has made quite a buzz this year with a major drug approval, acquisition, and significant advances in clinical trials.
Gene therapy encompasses various techniques and applications, including the replacement of faulty genes with healthy ones, the inactivation of malfunctioning genes, or the introduction of new genes to aid in disease resistance. With gene therapy being so versatile, in this article, we take a look at eight areas where gene therapy could bring new solutions to patients, some better known than others.
Huntington’s disease is a rare genetic condition that causes nerve cells in the brain to decay over time. For years, biotechs have been trying to develop treatments to cure Huntington’s disease but much to no avail. Trial failures and abandoned studies have loomed the Huntington’s community for decades but recent therapeutic milestones suggest that there might be light at the end of the tunnel.
Building on the foundations of its hugely successful AlphaFold2, which made a fundamental breakthrough in protein structure prediction in 2020, Google DeepMind and its sister company Isomorphic Labs launched AlphaFold3 in May. The platform recently became open-sourced, meaning academic researchers all over the world can access both the code and training weights for the first time for non-commercial applications. With the already unavoidable acclaim for AlphaFold3, can the platform really usher in a new era for drug discovery and molecular biology??
MicroRNAs (miRNAs) are small, non-coding RNA molecules, typically 21–23 nucleotides in length, that play a crucial role in regulating gene expression. They function by binding to complementary sequences on messenger RNA (mRNA) molecules, leading to mRNA degradation or inhibition of protein translation. Several companies are advancing candidates relying on miRNAs in 2024. In this article, we take a look at seven of these companies.?
In 2025, biotech events around the world will offer invaluable opportunities for networking and collaboration in biopharma. From gene editing breakthroughs to emerging therapies, these events are essential for staying at the forefront of innovation. Don’t miss the chance to connect with industry leaders and explore new business opportunities.
Immunology is a key area in biotech and biopharma, both in terms of R&D and sales. However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle. To have an immunological effect, you must activate the body’s T cells, which cells requires a chain of three key signals. While other companies have focused on only two of these signals, Greywolf Therapeutics is the first company to explore changing signal 1. To tell us more about this, we talked to Pete Joyce, CEO and co-founder of Greywolf Therapeutics.
ADCs combine monoclonal antibody precision with the potency of cytotoxic drugs. Their therapeutic potential has broadened with advancement in linker technology and payload optimization, vastly improving ADC efficacy and safety. As ADC technology undergoes refinement, the scope of targetable cancers expands. The hope is that next-generation ADCs can effectively go on to develop personalized oncology therapies that can treat previously untreatable tumors.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.